Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Yaupon Therapeutics, a specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from academic institutions, has named Steve Tullman as the new CEO and the chairman of the board of directors of the company.
Subscribe to our email newsletter
Tullman was the co-founder, president and CEO of Ception Therapeutics, which was acquired by Cephalon, in April 2010, and currently serves as chairman of Vicept Therapeutics.
Before Ception, Tullman was the co-founder of Trigenesis Therapeutics and Cutix Pharmaceuticals.
He started his career in the pharmaceutical industry at SmithKline Beecham (now GlaxoSmithKline) where he accumulated 14 years of broad industry experience in finance, sales, marketing, and R&D.
Yaupon board of directors James Huang said Steve has a remarkable track record of advancing and building value in biotechnology companies and they are pleased he has agreed to lead Yaupon.
"His vast knowledge and expertise within the pharma-biotech industry, notably in dermatology, is well aligned with our strategic business opportunities and the mechlorethamine gel opportunity," Huang said.